Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
J Neuroendovasc Ther ; 15(8): 525-532, 2021.
Article in English | MEDLINE | ID: mdl-37502760

ABSTRACT

Objective: In patients with acute ischemic stroke (AIS), prognosis strongly depends on the onset-to-recanalization time. The Ishinomaki protocol for rapid recanalization has been used since October 2017. This protocol determines the indication for reperfusion therapy based on computed tomography (CT)/three-dimensional CT angiography (3DCTA) findings and intends to reduce the onset-to-recanalization time. We aimed to compare the outcomes before and after protocol introduction. Methods: Our hospital is the only thrombectomy-capable center in Ishinomaki, Tome, and Kesennuma medical area. Before protocol introduction (April 2014-June 2016), both CT and magnetic resonance imaging were performed to determine the indications for intravenous (IV) recombinant tissue-plasminogen activator (rt-PA) or mechanical thrombectomy within 6 hours of disease onset. However, after protocol introduction (from October 2017), plain CT and 3DCTA were used. We collected data on patients who underwent mechanical thrombectomy and/or IV rt-PA before (n = 13) and after (n = 34) the protocol introduction. The required time from onset to door (OTD), door to needle (DTN), needle to puncture (NTP), puncture to recanalization (PTR), and door to recanalization (DTR) were compared before and after protocol introduction. Furthermore, thrombolysis in cerebral infarction (TICI) grades and modified Rankin scale (mRS) scores at discharge were compared. Results: The outcomes before and after protocol introduction were as follows: OTD: 105 ± 73.8 (mean ± standard deviation) vs. 120 ± 68.1 min (p = 0.376, Mann-Whitney U test); DTN: 62.9 ± 15.9 vs. 41 ± 17 min (p <0.01); NTP: 112 ± 69.8 vs. 39.9 ± 33.7 min (p <0.01); PTR: 87.9 ± 45.4 vs. 52.5 ± 27.9 min (p <0.01); and DTR, 230 ± 69.9 vs. 110 ± 40.3 min (p <0.0001). Before and after protocol introduction, the proportion of patients with TICI grade 2b-3, mRS score of 0-2 at discharge, and mRS score of 5-6 were 54% vs. 50% (p = 0.815, Fisher's exact test), 23% vs. 21% (p = 0.854), and 15% vs. 50% (p = 0.046), respectively. Conclusion: The Ishinomaki protocol reduced the mean DTR time by 120 min. The reduction in treatment time was due to the change in CT-based recanalization and collaboration with emergency physicians and paramedics. There was no increase in good outcomes, but there was a significant increase in poor outcomes at discharge. Patients who could not be salvaged were indicated for reperfusion therapy as CT and 3DCTA cannot detect the ischemic core.

2.
Brain ; 143(5): 1431-1446, 2020 05 01.
Article in English | MEDLINE | ID: mdl-32412053

ABSTRACT

Conformation-sensitive antibodies against myelin oligodendrocyte glycoprotein (MOG) are detectable in patients with optic neuritis, myelitis, opticomyelitis, acute or multiphasic disseminated encephalomyelitis (ADEM/MDEM) and brainstem/cerebral cortical encephalitis, but are rarely detected in patients with prototypic multiple sclerosis. So far, there has been no systematic study on the pathological relationship between demyelinating lesions and cellular/humoral immunity in MOG antibody-associated disease. Furthermore, it is unclear whether the pathomechanisms of MOG antibody-mediated demyelination are similar to the demyelination patterns of multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD) with AQP4 antibody, or ADEM. In this study, we immunohistochemically analysed biopsied brain tissues from 11 patients with MOG antibody-associated disease and other inflammatory demyelinating diseases. Patient median onset age was 29 years (range 9-64), and the median interval from attack to biopsy was 1 month (range 0.5-96). The clinical diagnoses were ADEM (n = 2), MDEM (n = 1), multiple brain lesions without encephalopathy (n = 3), leukoencephalopathy (n = 3) and cortical encephalitis (n = 2). All these cases had multiple/extensive lesions on MRI and were oligoclonal IgG band-negative. Most demyelinating lesions in 10 of 11 cases showed a perivenous demyelinating pattern previously reported in ADEM (153/167 lesions) and a fusion pattern (11/167 lesions) mainly in the cortico-medullary junctions and white matter, and only three lesions in two cases showed confluent demyelinated plaques. In addition, 60 of 167 demyelinating lesions (mainly in the early phase) showed MOG-dominant myelin loss, but relatively preserved oligodendrocytes, which were distinct from those of AQP4 antibody-positive NMOSD exhibiting myelin-associated glycoprotein-dominant oligodendrogliopathy. In MOG antibody-associated diseases, MOG-laden macrophages were found in the perivascular spaces and demyelinating lesions, and infiltrated cells were abundant surrounding multiple blood vessels in and around the demyelinating lesions, mainly consisting of macrophages (CD68; 1814 ± 1188 cells/mm2), B cells (CD20; 468 ± 817 cells/mm2), and T cells (CD3; 2286 ± 1951 cells/mm2), with CD4-dominance (CD4+ versus CD8+; 1281 ± 1196 cells/mm2 versus 851 ± 762 cells/mm2, P < 0.01). Humoral immunity, evidenced by perivascular deposits of activated complements and immunoglobulins, was occasionally observed in some MOG antibody-associated demyelinating lesions, and the frequency was much lower than that in AQP4 antibody-positive NMOSD. Subpial lesions with perivenous demyelination were observed in both ADEM and cortical encephalitis. Our study suggests that ADEM-like perivenous inflammatory demyelination with MOG-dominant myelin loss is a characteristic finding of MOG antibody-associated disease regardless of whether the diagnostic criteria of ADEM are met. These pathological features are clearly different from those of multiple sclerosis and AQP4 antibody-positive NMOSD, suggesting an independent autoimmune demyelinating disease entity.


Subject(s)
Brain/pathology , Demyelinating Autoimmune Diseases, CNS/immunology , Demyelinating Autoimmune Diseases, CNS/pathology , Myelin-Oligodendrocyte Glycoprotein/immunology , Adolescent , Adult , Autoantibodies/immunology , Autoantigens/immunology , Child , Female , Humans , Male , Middle Aged , Young Adult
5.
J Tissue Eng Regen Med ; 6(7): 550-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21809452

ABSTRACT

Tissue-engineered medical products (TEMPs) should be evaluated before implantation. Therefore, it is indispensable to establish evaluation protocols in regenerative medicine. Whether or not such evaluation protocols are reasonable is generally verified through a 'round robin' test. However, the round robin test for TEMPs intrinsically includes a deficiency, because 'identical' specimens can not be prepared for TEMPs. The aim of the study was to assess the feasibility and limitations of the round robin test for TEMPs by using a prepared evaluation protocol. We adopted tissue-engineered cartilage constructs as delivered specimens and a protocol of measuring sGAG content as an evaluation protocol proposed to ISO TC150/SC7, which is an invasive, but usually applied, method, although non-invasive methods are keenly required in evaluating TEMPs. The results showed that: (a) the coefficient of variation (CV) of the measured sGAG contents in intralaboratory tests was ~5% at most; (b) the CV of sGAG content in the scheme where each participating laboratory measured different constructs was comparable with that in the scheme where each participating laboratory measured one half of a construct along with the organizing laboratory; (c) the CV caused by factors other than the specimen was ~15%, comparable to that in reproducible experiments in biomedical fields. Based on these results, the study concludes that a round robin test for a TEMP could be valuable, under the condition that the delivered TEMPs are sufficiently reproducible so that the CV of the measured values is < 5% in the organizing laboratory.


Subject(s)
Biocompatible Materials/pharmacology , Chondrogenesis/drug effects , Chondrogenesis/physiology , Materials Testing/methods , Tissue Engineering/methods , Animals , Cattle , Evaluation Studies as Topic , Feasibility Studies , Gels , Glycosaminoglycans/metabolism , Laboratories
7.
J Clin Neurosci ; 12(7): 820-2, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16153849

ABSTRACT

Recurrent episodes of aphasia due to partial status epilepticus is an uncommon clinical entity. We report here a 78-year-old-woman with episodic aphasia which occurred periodically. During the ictal period, she was conscious, but had difficulty in speech and could not comprehend verbal commands. The ictal EEG showed continuous spike and sharp waves over the left frontotemporal area. After the administration of antiepileptic drugs, her language activity returned to near the baseline level and the epileptic discharges were significantly reduced. Nonconvulsive partial status epilepticus should be considered in the differential diagnosis of recurrent aphasia, even if the symptoms occur periodically.


Subject(s)
Aphasia/etiology , Status Epilepticus/complications , Aged , Aphasia/diagnostic imaging , Electroencephalography/methods , Female , Frontal Lobe/diagnostic imaging , Frontal Lobe/pathology , Humans , Status Epilepticus/diagnostic imaging , Temporal Lobe/diagnostic imaging , Temporal Lobe/pathology , Tomography, Emission-Computed, Single-Photon/methods
8.
J Neuroimmunol ; 159(1-2): 177-82, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15652417

ABSTRACT

We measured four chemokines in the cerebrospinal fluid (CSF) in human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) with ELISA. CXCL10/IP-10, a T cell type 1 (Th1)-associated chemokine, was significantly elevated in HAM/TSP compared with controls, and the values were even significantly higher in HAM/TSP than in multiple sclerosis (MS) in which CXCL10/IP-10 up-regulation was previously reported. Among Th2-associated chemokines, CCL17/TARC and CCL11/Eotaxin in HAM/TSP were not different from those in controls. As shown in MS, CCL2/MCP-1 was significantly lower in HAM/TSP than in control. Following interferon (IFN)-alpha therapy in HAM/TSP, CCL2/MCP-1 became significantly higher than that before therapy, which may reflect a Th2 induction, while CXCL10/IP-10 remained elevated.


Subject(s)
Chemokines, CXC/biosynthesis , Chemokines, CXC/cerebrospinal fluid , Interferon-alpha/therapeutic use , Paraparesis, Tropical Spastic/cerebrospinal fluid , Paraparesis, Tropical Spastic/immunology , Up-Regulation/immunology , Adult , Aged , Chemokine CCL11 , Chemokine CCL17 , Chemokine CCL2/biosynthesis , Chemokine CCL2/blood , Chemokine CCL2/cerebrospinal fluid , Chemokine CXCL10 , Chemokines, CC/blood , Chemokines, CC/cerebrospinal fluid , Chemokines, CXC/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Multiple Sclerosis/cerebrospinal fluid , Multiple Sclerosis/immunology , Multiple Sclerosis/therapy , Paraparesis, Tropical Spastic/therapy , Reagent Kits, Diagnostic
9.
J Neuroimmunol ; 158(1-2): 240-4, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15589059

ABSTRACT

We analyzed the concentrations of four chemokines in the cerebrospinal fluid (CSF) and sera in Vogt-Koyanagi-Harada disease (VKH), an autoimmune uveomeningitis syndrome against melanocyte-associated proteins, with ELISA. CSF-CXCL10/IP-10 and CSF-CCL17/TARC were significantly elevated in VKH than in controls. In the majority of VKH cases and controls, CSF-CXCL10 was higher than serum-CXCL10, and CSF-CCL17 was lower than serum-CCL17. CCL11/Eotaxin was not different between groups. CSF-CCL2/MCP-1 was significantly lower in VKH than in control. The changes in VKH were essentially similar to those in multiple sclerosis, a known Th1-dominant condition.


Subject(s)
Chemokines/blood , Chemokines/cerebrospinal fluid , Uveomeningoencephalitic Syndrome/blood , Uveomeningoencephalitic Syndrome/cerebrospinal fluid , Adolescent , Adult , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Male , Middle Aged , Statistics, Nonparametric
10.
J Neuroimmunol ; 149(1-2): 182-6, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15020078

ABSTRACT

The pathogenesis of relapsing neuromyelitis optica (RNMO) remains unknown. We, for the first time, studied the levels of four chemokines in the cerebrospinal fluid in RNMO with ELISA and compared the data with those in multiple sclerosis (MS) and control. CXCL10/IP-10 and CCL17/TARC were significantly elevated in both RNMO and MS. Conversely, CCL2/MCP-1 was significantly lower in MS, but not in RNMO, than in control. CCL11/Eotaxin was not different between groups. None of the four chemokines studied was significantly different between RNMO and MS.


Subject(s)
Chemokines/cerebrospinal fluid , Multiple Sclerosis/cerebrospinal fluid , Neuromyelitis Optica/cerebrospinal fluid , Age of Onset , Chemokines/blood , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Male , Multiple Sclerosis/blood , Neuromyelitis Optica/blood , Statistics, Nonparametric
11.
Intern Med ; 42(10): 1035-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14606722

ABSTRACT

Familial occurrence of inclusion body myositis is extremely rare, and only a few cases in Western countries have been reported. In these reports, a strong association of this disease with DR3 (DRB1*0301/0302) and the efficacy of immunosuppressants suggested that an immune pathomechanism is involved in the disease. We, for the first time, report two Japanese sisters who suffered myopathy clinicopathologically similar to inclusion body myositis. One sister received corticosteroid and azathioprine and the therapy relieved dysphagia. Both of our patients had DR15(2)/4 (DRB1*1502/0405), suggesting a distinct genetic association with the disease in the Japanese population.


Subject(s)
HLA Antigens/immunology , Muscle, Skeletal/pathology , Myositis, Inclusion Body/genetics , Myositis, Inclusion Body/immunology , Aged , Biopsy , Female , Genetic Predisposition to Disease , Humans , Immunosuppressive Agents/therapeutic use , Myositis, Inclusion Body/drug therapy , Treatment Outcome
12.
Rinsho Shinkeigaku ; 43(1-2): 12-5, 2003.
Article in Japanese | MEDLINE | ID: mdl-12820544

ABSTRACT

Migraine is usually not associated with CSF pleocytosis. However, patients with migraine-like severe headache who showed temporary neurological deficits and pleocytosis have recently been accumulated in the literature. Here we report a 20-year-old woman who was admitted to our hospital because of aphasia and right hemiparesis with severe throbbing headache in the left on 15 February, 2001. During the preceding 3 days she experienced another two similar episodes. Lumbar puncure revealed lymphocyte dominant pleocytosis of 56 cells/microliter. These symptoms recovered completely within several hours. EEG showed intermittent theta waves of 4-5c/s, 50-80 microV in the bilateral fronto-parietal region, but no epileptiform activity. On the 12th day 123I-IMP SECT demonstrated rather hyperperfusion in the left fronto-temporo-parietal region. Again, in the early morning on 10 December she was carried to our hospital by an ambulance car because of severe headache, right hemiparesis, expressive and receptive aphasia and drowsiness. Body temperature was 37.9 degrees C and lumbar puncture revealed increased opening pressure of 230 mmH2O and cells of 17/microliter. All the symptoms cleared within 24 hours and she left hospital without any sequelae. The symptoms of this case are consistent with those of headache with neurologic deficits and CSF lymphocytosis (HaNDL) by Berg et al, or pseudomigraine with pleocytosis (PMP syndrome) by Gometz-Aranda et al. No reports have been published on this disease in Japan.


Subject(s)
Leukocytosis/cerebrospinal fluid , Migraine Disorders/complications , Adult , Aphasia/etiology , Hemiplegia/etiology , Humans , Iofetamine , Leukocytosis/complications , Migraine Disorders/diagnostic imaging , Radiopharmaceuticals , Tomography, Emission-Computed, Single-Photon
SELECTION OF CITATIONS
SEARCH DETAIL
...